ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 28252003

Integrating liquid biopsies into the management of cancer.

Siravegna G and 3 others. Nat Rev Clin Oncol, 2017. Cited by 1,543 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Integrating liquid biopsies into the management of cancer. Papers, record 28252003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28252003

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Integrating liquid biopsies into the management of cancer.
PubMed
Journal
Nat Rev Clin Oncol
PubMed
Year
2017
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1,543
iCite
Relative citation ratio, by iCite
54
iCite
Revised in PubMed
2025-06-10
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Siravegna GGiulia
2Marsoni SSilvia
3Siena SSalvatore
4Bardelli AAlberto

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biomarkers, TumorMajor topic
BiopsyMajor topic
Neoplastic Cells, CirculatingMajor topic
Blood Specimen Collection
DNA, Neoplasm
Disease Management
Humans
Neoplasms

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT05234177Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS AssaysBackgroundClinicalTrials.gov
NCT05236114GEMINI-NSCLC: NSCLC Biomarker StudyBackgroundClinicalTrials.gov
NCT05257551Tempus Small Cell Lung Cancer Observational Study (Sculptor)BackgroundClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References209

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115,317,891Circulating tumor cells, disease progression, and survival in metastatic breast cancer.N Engl J Med2004https://conductscience.org/library/papers/15317891PubMed
218,829,513Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.Clin Cancer Res2008https://conductscience.org/library/papers/18829513PubMed
38,722,221Detection of tyrosinase mRNA from the blood of melanoma patients.Cancer Epidemiol Biomarkers Prev1996https://conductscience.org/library/papers/8722221PubMed
419,011,622Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.Nat Cell Biol2008https://conductscience.org/library/papers/19011622PubMed
525,201,530Organoid cultures derived from patients with advanced prostate cancer.Cell2014https://conductscience.org/library/papers/25201530PubMed
621,148,127Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus.Sci Transl Med2010https://conductscience.org/library/papers/21148127PubMed
720,051,957Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype.Br J Cancer2010https://conductscience.org/library/papers/20051957PubMed
824,773,774Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.BMC Cancer2014https://conductscience.org/library/papers/24773774PubMed
920,497,919Circulating tumor cells in the management of breast cancer.Clin Breast Cancer2010https://conductscience.org/library/papers/20497919PubMed
1024,698,732Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.Mol Oncol2014https://conductscience.org/library/papers/24698732PubMed

1 to 10 of 209

See all 209 references

Cited by1,065

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,543 citations.

PMIDTitleJournalYearIn PapersSource
42,938,827Early-Phase Drug Development in Rare Cancers: A Decade of Progress and Future Directions.Cancers (Basel)2026https://conductscience.org/library/papers/42938827PubMed
42,927,017Peripheral and selective venous liquid biopsy profiling in localized prostate cancer: A pilot feasibility study.J Liq Biopsy2026https://conductscience.org/library/papers/42927017PubMed
42,926,854Circulating tumor DNA in body fluids for molecular characterization of cancers beyond tissue and blood.iScience2026https://conductscience.org/library/papers/42926854PubMed
42,905,048Attitudes of cancer patients toward ctDNA-based liquid biopsy for follow-up.Mol Oncol2026https://conductscience.org/library/papers/42905048PubMed
42,898,796Fibrinogen Alpha Chain (FGA) Associates With Epithelial-Mesenchymal Transition, Stemness, and the USP-Catenin Complex in Colorectal Cancer.Stem Cells Int2026https://conductscience.org/library/papers/42898796PubMed
42,883,913Prognostic Value and Longitudinal Dynamics of Multigene Circulating Tumor DNA in Advanced Pancreatic Cancer Treated with 5-Fluorouracil-Based Chemotherapy.Int J Mol Sci2026https://conductscience.org/library/papers/42883913PubMed
42,882,929Multi-Omics and Liquid Biopsy Integration for Precision Stratification of Breast Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42882929PubMed
42,882,819The Landscape of Tumor Dissemination in Leptomeningeal Disease: Mapping CTC Plasticity and Regional Heterogeneity Across Blood and CSF Compartments.Cancers (Basel)2026https://conductscience.org/library/papers/42882819PubMed
42,870,868Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy.Front Oncol2026https://conductscience.org/library/papers/42870868PubMed
42,868,712Soluble N-terminal EphA2 fragment as a diagnostic biomarker and functional mediator of tumor progression in triple-negative breast cancer.Transl Oncol2026https://conductscience.org/library/papers/42868712PubMed

1 to 10 of 1,065

See all 1,065 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28252003

GET https://conductscience.org/api/papers/v1/28252003/references?page=2

API referenceFor AI assistants